<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504231</url>
  </required_header>
  <id_info>
    <org_study_id>ID/RD01</org_study_id>
    <nct_id>NCT00504231</nct_id>
  </id_info>
  <brief_title>Intradermal Influenza Vaccine Study in Elders</brief_title>
  <official_title>Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial compared the immunogenicity of 60% dose intradermal (ID) influenza
      vaccination to standard intramuscular (IM) vaccination of full-dose or 60% dose vaccine. Pre-
      and postvaccination measurements in the hemagglutination inhibition antibody (HAI) titer were
      compared. Participants who received reduced-dose vaccine were revaccinated with full-dose IM
      vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open-label randomized trial consisting of community-dwelling adults 65
      years and older living in Puget Sound area in Washington State. Subjects were enrolled and
      randomly assigned to receive licensed, 2007-2008 Northern Hemisphere TIV vaccine (Fluzone,
      lot U2440AA; Sanofi Pasteur) containing concentrations of hemagglutinin of each of A/Solomon
      Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), and B/Malaysia/2506/2004 (B): 15
      ug/0.5 mL by the IM route, 9 ug/0.3 mL by the ID or IM route, or 4.5 ug/0.15 mL given twice
      by ID route to the nondominant arm. A block randomization scheme (1:1:1:1), stratified by
      sex, was used. For IM vaccination, 0.3 mL or 0.5 mL of vaccine was removed from a multidose
      (5 mL) vial through a 25-gauge, 1-inch detachable needle (Becton Dickinson) and was injected
      into the deltoid muscle at a 90 degree angle to the skin. For ID vaccination, 0.3 mL or 0.15
      mL was drawn by a TB syringe through a 25-gauge, 5/8-inch needle (Terumo Medical). The needle
      was inserted at a 15 degree angle to the skin overlying the deltoid of the arm. The vaccine
      was slowly injected until all material was expelled and induration appeared. Subjects
      randomized to the 0.15-mL group received 2 side-by-side ID injections 3 cm apart.
      Participants returned at 4 weeks to determine postvaccination antibody titers. At this
      follow-up visit, those assigned to reduced dose IM or ID influenza vaccinations then received
      full-dose IM influenza vaccination. These participants returned in another 4 weeks to repeat
      HAI titers. A nonrandomized subset of subjects (based on availability and willingness to
      participate) returned at 14 days after initial vaccination for T cell assays in an
      exploratory substudy to examine cellular immune response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Pre- and Post- Vaccination</measure>
    <time_frame>1 month</time_frame>
    <description>Seroprotection before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) Intramuscular (IM) or Reduced-Dose (9 mg) Intradermal (ID) Injections for A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) Pre- and Post- Vaccination</measure>
    <time_frame>1 month</time_frame>
    <description>GMT before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) IM or Reduced-Dose (9 mg) ID Injections. A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Reactogenicity</measure>
    <time_frame>1 week</time_frame>
    <description>Maximum solicited systemic and local signs and symptoms during the week after initial vaccination, by Dose and Randomization Assignment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>0.3 mL Influenza Vaccine ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60% dose - 0.3 mL delivered intradermally with needle and syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.15 mL twice Influenza Vaccine ID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60% dose - 0.15 mL delivered twice intradermally with needle and syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mL Influenza Vaccine by IM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100% dose - 0.5mL delivered intramuscularly with needle and syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mL Influenza Vaccine IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60% dose - 0.3 mL delivered intramuscularly with needle and syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Influenza Vaccine (2007-2008)</intervention_name>
    <description>Manufactured by Sanofi Pasteur</description>
    <arm_group_label>0.3 mL Influenza Vaccine ID</arm_group_label>
    <arm_group_label>0.15 mL twice Influenza Vaccine ID</arm_group_label>
    <arm_group_label>0.5 mL Influenza Vaccine by IM</arm_group_label>
    <arm_group_label>0.3 mL Influenza Vaccine IM</arm_group_label>
    <other_name>Fluzone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, medically stable persons 65 years of age or older

          -  Able to read and understand informed consent

          -  Available during the trial period and for follow-up

          -  Able to understand and comply with planned study procedures

          -  Able to be contacted by telephone for follow-up of adverse events

        Exclusion Criteria:

          -  Known allergy to eggs or other components of vaccine (i.e., thimerosal)

          -  History of Guillain-Barr√© Syndrome (GBS)

          -  Has a confirmed or suspected immunodeficient or immunosuppressive condition (including
             congenital or acquired immunosuppressive therapy, and human immunodeficiency virus
             [HIV])

          -  End-stage renal disease requiring hemodialysis

          -  Active neoplastic disease or history of any hematologic malignancy (except localized
             skin or prostate cancer that is stable in the absence of therapy)

          -  Acute or chronic condition that (in the opinion of the investigator) would render
             vaccination unsafe or would interfere with the evaluation of responses (including but
             not limited to the following: known chronic liver disease, significant renal disease,
             oxygen-dependent chronic lung disease, New York Heart Association Functional Class III
             or IV, unstable or progressive neurologic disorder, insulin controlled diabetes
             mellitus)

          -  Use of experimental vaccines within the month prior to study entry, or expected use of
             experimental or licensed vaccines or blood/blood products during the duration of the
             study.

          -  Receipt of immunoglobulin or other blood product within 3 months prior to enrollment

          -  Receipt of other licensed vaccines within the preceding 4 weeks

          -  History of a severe reaction following influenza vaccination

          -  Current or planned participation in a research study of an investigational drug.
             Participation in research studies that involve use of licensed drugs, for either
             approved or investigational indications, will be permitted with the approval of the
             PI, as will participation in research studies that do not involve vaccines or
             medications.

          -  Current use or previous chronic administration, defined as &gt;14 days during the
             previous six months, of immunosuppressants or other immune-modifying drugs. (For oral
             or injected corticosteroids, the immune-modifying dose is defined as prednisone or its
             equivalent &gt;10 mg/day or &gt;800mcg per day of inhaled beclomethasone dipropionate or
             equivalent ). Topical steroids are allowed.

          -  Use of cytotoxic therapy in the previous 2 years.

          -  Plans to receive cytotoxic therapy during the study period.

          -  Concurrent moderate to severe illness. Need to defer vaccination until recovery.
             (Vaccination is not contraindicated in subjects with mild illnesses or with low-grade
             fever).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ru-Chien Chi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VAPSHCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Neuzil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <results_first_submitted>January 11, 2012</results_first_submitted>
  <results_first_submitted_qc>June 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2012</results_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>prevention</keyword>
  <keyword>intradermal</keyword>
  <keyword>vaccine</keyword>
  <keyword>delivery</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Full-dose 0.5 mL IM</title>
          <description>0.5 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="P2">
          <title>60% Dose 0.3 mL IM</title>
          <description>0.3 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="P3">
          <title>60% Dose 0.3 mL ID</title>
          <description>0.3 mL influenza vaccine delivered intradermally</description>
        </group>
        <group group_id="P4">
          <title>60% Dose 0.15 mL x 2 ID</title>
          <description>0.15 mL influenza vaccine twice delivered intradermally with needle and syringe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discrepant chart documentation re route</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Full-dose 0.5 mL IM</title>
          <description>0.5 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="B2">
          <title>60% Dose 0.3 mL IM</title>
          <description>0.3 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="B3">
          <title>60% Dose 0.3 mL ID</title>
          <description>0.3 mL influenza vaccine delivered intradermally</description>
        </group>
        <group group_id="B4">
          <title>60% Dose 0.15 mL x 2 ID</title>
          <description>0.15 mL influenza vaccine twice delivered intradermally with needle and syringe</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.6" spread="6.8"/>
                    <measurement group_id="B2" value="75.2" spread="7.7"/>
                    <measurement group_id="B3" value="73.6" spread="6.3"/>
                    <measurement group_id="B4" value="74.7" spread="6.3"/>
                    <measurement group_id="B5" value="74.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Pre- and Post- Vaccination</title>
        <description>Seroprotection before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) Intramuscular (IM) or Reduced-Dose (9 mg) Intradermal (ID) Injections for A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full-dose 0.5 mL IM</title>
            <description>100% dose - 0.5mL delivered intramuscularly with needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>60% Dose 0.3 mL IM</title>
            <description>60% dose - 0.3 mL delivered intramuscularly with needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>60% Dose 0.3 mL ID</title>
            <description>60% dose - 0.3 mL delivered intradermally with needle and syringe</description>
          </group>
          <group group_id="O4">
            <title>60% Dose 0.15 mL x 2 ID</title>
            <description>60% dose - 0.15 mL delivered twice intradermally with needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Pre- and Post- Vaccination</title>
          <description>Seroprotection before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) Intramuscular (IM) or Reduced-Dose (9 mg) Intradermal (ID) Injections for A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
          <units>% of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Seroprotection Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="34.6" upper_limit="66.5"/>
                    <measurement group_id="O2" value="12.5" lower_limit="40.0" upper_limit="73.4"/>
                    <measurement group_id="O3" value="19.1"/>
                    <measurement group_id="O4" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Seroprotection 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="57.8"/>
                    <measurement group_id="O3" value="68.9"/>
                    <measurement group_id="O4" value="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Seroprotection Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="49.2"/>
                    <measurement group_id="O4" value="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Seroprotection 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="75.4"/>
                    <measurement group_id="O4" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Seroprotection Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Seroprotection 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="16.5"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) Pre- and Post- Vaccination</title>
        <description>GMT before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) IM or Reduced-Dose (9 mg) ID Injections. A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full-dose 0.5 mL IM</title>
            <description>100% dose - 0.5mL delivered intramuscularly with needle and syringe</description>
          </group>
          <group group_id="O2">
            <title>60% Dose 0.3 mL IM</title>
            <description>60% dose - 0.3 mL delivered intramuscularly with needle and syringe</description>
          </group>
          <group group_id="O3">
            <title>60% Dose 0.3 mL ID</title>
            <description>60% dose - 0.3 mL delivered intradermally with needle and syringe</description>
          </group>
          <group group_id="O4">
            <title>60% Dose 0.15 mL x 2 ID</title>
            <description>60% dose - 0.15 mL delivered twice intradermally with needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) Pre- and Post- Vaccination</title>
          <description>GMT before and 4 Weeks after Vaccination by Full- or Reduced-Dose (9 mg) IM or Reduced-Dose (9 mg) ID Injections. A/Solomon Islands/3/2006 (A/H1N1), A/Wisconsin/67/2005 (A/H3N2), B/Malaysia/2506/2004 (B)</description>
          <units>GMT</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="9.8" upper_limit="16.0"/>
                    <measurement group_id="O2" value="11.3" lower_limit="8.9" upper_limit="14.3"/>
                    <measurement group_id="O3" value="13.6" lower_limit="10.7" upper_limit="17.4"/>
                    <measurement group_id="O4" value="11.2" lower_limit="9.1" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="40.0" upper_limit="73.4"/>
                    <measurement group_id="O2" value="41.8" lower_limit="29.5" upper_limit="59.2"/>
                    <measurement group_id="O3" value="48.0" lower_limit="34.6" upper_limit="66.5"/>
                    <measurement group_id="O4" value="48.6" lower_limit="36.2" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="23.9" upper_limit="47.6"/>
                    <measurement group_id="O2" value="27.1" lower_limit="20.1" upper_limit="36.4"/>
                    <measurement group_id="O3" value="29.4" lower_limit="21.1" upper_limit="40.8"/>
                    <measurement group_id="O4" value="29.0" lower_limit="21.2" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" lower_limit="57.6" upper_limit="108.6"/>
                    <measurement group_id="O2" value="62.4" lower_limit="46.6" upper_limit="83.5"/>
                    <measurement group_id="O3" value="57.5" lower_limit="42.4" upper_limit="78.1"/>
                    <measurement group_id="O4" value="72.6" lower_limit="53.2" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Prevaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.6" upper_limit="13.2"/>
                    <measurement group_id="O2" value="10.1" lower_limit="8.2" upper_limit="12.5"/>
                    <measurement group_id="O3" value="9.8" lower_limit="7.8" upper_limit="12.3"/>
                    <measurement group_id="O4" value="12.8" lower_limit="9.9" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B 4 weeks after vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="12.7" upper_limit="21.4"/>
                    <measurement group_id="O2" value="12.4" lower_limit="10.0" upper_limit="15.5"/>
                    <measurement group_id="O3" value="10.8" lower_limit="8.5" upper_limit="13.8"/>
                    <measurement group_id="O4" value="15.9" lower_limit="12.1" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Reactogenicity</title>
        <description>Maximum solicited systemic and local signs and symptoms during the week after initial vaccination, by Dose and Randomization Assignment</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Full-dose 0.5 mL IM</title>
            <description>0.5 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
          </group>
          <group group_id="O2">
            <title>60% Dose 0.3 mL IM</title>
            <description>0.3 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
          </group>
          <group group_id="O3">
            <title>60% Dose 0.3 mL ID</title>
            <description>0.3 mL influenza vaccine delivered intradermally</description>
          </group>
          <group group_id="O4">
            <title>60% Dose 0.15 mL x 2 ID</title>
            <description>0.15 mL influenza vaccine twice delivered intradermally with needle and syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Reactogenicity</title>
          <description>Maximum solicited systemic and local signs and symptoms during the week after initial vaccination, by Dose and Randomization Assignment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever, &gt;=38.0C and &lt;39.0C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, &gt;=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, present but easily tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, interferes with normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, present but easily tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, interferes with normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General body ache/pain, present but easily tolerat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General body ache/pain, interferes with normal a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, present but easily tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, interferes with normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, present but easily tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, interferes with normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness or Discoloration, &lt;=8 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness or Discoloration, &gt;8 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized swelling, &lt;=8 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized swelling, &gt;8 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site, present but easily tolerat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at injection site, interferes with normal act</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching at injection site, present but tolerated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching at injection site, interferes with normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm motion limitation, some limitiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm motion limitation, interferes normal activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Full-dose 0.5 mL IM</title>
          <description>0.5 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="E2">
          <title>60% Dose 0.3 mL IM</title>
          <description>0.3 mL influenza vaccine delivered intramuscularly with needle/syringe</description>
        </group>
        <group group_id="E3">
          <title>60% Dose 0.3 mL ID</title>
          <description>0.3 mL influenza vaccine delivered intradermally</description>
        </group>
        <group group_id="E4">
          <title>60% Dose 0.15 mL x 2 ID</title>
          <description>0.15 mL influenza vaccine twice delivered intradermally with needle and syringe</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>Resulted in hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>anemia and arrhythmia</sub_title>
                <description>Resulted in hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Resulted in hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <description>resulted in hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>complicated fall</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ru-Chien Chi B.S., M.D., M.S.</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 768-5217</phone>
      <email>rchi@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

